Marvel Biosciences' MB-204 Reverses Behavioural and Cognitive Deficits in Fragile X Mouse Model, Marking Third Preclinical ASD Success
Key Insights
MB-204 demonstrated statistically significant restoration of behavioural and cognitive function toward wild-type levels in a Fragile X syndrome (search) (Fmr1 KO) mouse model across all endpoints tested.
The high-dose group achieved wildtype-like performance in open-field activity, self-grooming, nesting, and hyponeophagia (p<0.0001 vs KO vehicle), with durable carry-over effects persisting two weeks after treatment cessation.
This represents the third independent preclinical autism spectrum disorder (search) model in which MB-204 has shown efficacy, following positive results in Rett syndrome (search) (Mecp2) and Oprm1 ASD models.
Marvel Biosciences Corp. (search) (TSXV: MRVL | OTC: MBCOF) announced positive preclinical results demonstrating that its lead drug candidate, MB-204, reversed behavioural and cognitive deficits in a Fragile X syndrome (search) mouse model. The study, conducted through the FRAXA Drug Validation Initiative (FRAXA-DVI) in collaboration with the FRAXA Research Foundation, showed that MB-204 restored every behavioural and cognitive endpoint studied in FMR1 knockout (KO) mice toward wild-type (normal) levels. This marks the third independent preclinical autism spectrum disorder (search) (ASD) model in which MB-204 has generated compelling efficacy data, following previously reported positive results in Rett syndrome (search) (Mecp2) and the Oprm1 model of ASD.
Fragile X syndrome (search) (FXS) is the most common inherited cause of intellectual disability and one of the most common single-gene causes of autism spectrum disorder (search). It is caused by mutations in the FMR1 gene on the X chromosome, with males typically more severely affected than females. Current epidemiological studies estimate that FXS occurs in approximately 1 in 7,000 males and 1 in 11,000 females in the general population, qualifying it as an orphan disease in both the United States and Europe.
Study Design and Key Findings
The study evaluated MB-204 in low- and high-dose treatment groups administered orally once daily in FMR1 KO mice. Animals were treated for approximately two weeks and subjected to a standard battery of model-specific behavioural and cognitive tests, then retested two weeks after treatment cessation to assess the carry-over effect of the drug. Endpoints included novel object recognition (cognition), open-field test (locomotor activity), self-grooming (stereotypy), nesting (hippocampal-dependent activity of daily living), and hyponeophagia (anxiety).
After two weeks of treatment, MB-204 produced clear dose-dependent behavioural effects on every endpoint, with the high-dose group showing the strongest and most consistent efficacy. Animals receiving the high-dose treatment generated response patterns statistically consistent with wildtype-like performance in open-field test activity, self-grooming, nesting, and hyponeophagia (p<0.0001 vs KO vehicle), although nesting remained different from wild-type. The low-dose group produced significant but non-wildtype-like effects in open field, self-grooming, and hyponeophagia (p<0.0001, p<0.017, and p<0.0001 vs KO vehicle, respectively) but had no detectable effect on nesting. Both treatment groups restored novel-object discrimination (p<0.0001 for both doses), demonstrating significant improvement in recognition memory, a key measure of cognitive function.
Durable Carry-Over Effects After Treatment Cessation
Two weeks after treatment ceased, the high-dose group retained significant effects relative to KO vehicle in open field (p=0.003) and self-grooming (p=0.0015), although these responses were attenuated and no longer wildtype-like. Notably, the high-dose group also retained significant novel-object discrimination when tested with a completely different object set (p=0.0052), supporting a persistent recognition-memory effect rather than simple memory for the original objects. The low-dose treatment was insufficient to produce a durable post-treatment benefit.
Overall, the results support robust on-treatment efficacy and a measurable, though reduced, post-washout effect in the high-dose treatment group.
Building a Preclinical Package Across Multiple ASD Models
"This is now the third ASD model and second independent group that has demonstrated the potential of MB-204 to restore behavioural and cognitive function to near normal levels in mice regardless of the genetic cause of the neurodevelopmental disorder," commented Dr. Mark Williams, CSO of Marvel Biosciences. "We also confirmed a carry-over effect in a second model, suggesting MB-204 has a very attractive target product profile. We are very grateful to FRAXA for this collaboration and look forward to advancing MB-204 to the clinic."
The Company has also completed preclinical evaluation of MB-204 in a Shank3 model of Phelan-McDermid syndrome (search) and is awaiting final statistical analysis of the results, with those findings expected in a future announcement.
Mechanism of Action and Therapeutic Rationale
MB-204 is a novel fluorinated derivative of Istradefylline, an approved Parkinson's disease drug and the only adenosine A2A receptor (search) blocker currently on the market. Research indicates that blocking the A2A receptor may help treat conditions such as autism, depression, and Alzheimer's disease. Marvel is exploring MB-204's potential in rare disorders including Rett syndrome (search) and Fragile X syndrome (search), aiming to bring new therapeutic options to patients with few effective treatments.
The collective preclinical data across three independent ASD models — Rett syndrome (search), Oprm1 ASD, and now Fragile X syndrome (search) — continue to build a compelling package supporting the advancement of MB-204 toward clinical trials, while expanding its potential commercial opportunity across multiple orphan neurological indications with significant unmet medical need.